Anemia
Conditions
Brief summary
This study will evaluate the effect of epoetin beta (NeoRecormon) on correction of anemia and quality of life in participants with diabetes and chronic renal failure and who are not receiving dialysis.
Interventions
DRUGEpoetin beta
Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 1 or 2 diabetes * Chronic renal failure (stage 2 to stage 5) defined by Glomerular Filtration Rate (GFR) less than (\<) 90 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) * Anemia related to chronic kidney disease and requiring treatment with erythropoiesis-stimulating agent (ESA) (2 values of hemoglobin less than or equal to 11 gram per deciliter \[g/dL\] during the 3 months prior to inclusion), and hemoglobin greater than 8 g/dL
Exclusion criteria
* Anemia due to a non-renal cause * Poorly controlled hypertension * Treatment with an erythropoiesis stimulating agent (ESA) within 3 months prior to the study * Planned dialysis in next 3 months or organ transplant * History of cancer except for basal cell cancer and cervical cancer in situ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants With Hemoglobin Greater Than (>) 11 Grams per Deciliter (g/dL) After 8-Week Correction Phase | Week 8 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants With Hemoglobin >11 g/dL After 4-Week Continuation Phase | Week 12 |
| Quality of Life of Participants as Assessed From Short Form 36 (SF-36) Scores | Baseline, Week 8, 12 |
| Percentage of Participants With Positive Response to Questionnaire for Practicality and Safety of Self-administration of Study Drug | Week 8, 12 |
| Number of Participants With Local Injection Site Reactions | Up to 12 weeks |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 12 weeks |
| Percentage of Participants With Hemoglobin >11 g/dL After 4-Week Extension Phase | Week 12 |
| Response to Treatment at the end of the Correction Phase Among Participants With Different Time Since Diabetes Diagnosis | Week 8 |
| Response to Treatment at the end of the Correction Phase Among Participants With Different Hemoglobin Levels at Baseline | Week 8 |
| Response to Treatment at the end of the Correction Phase Among Participants With Different Hematocrit at Baseline | Week 8 |
| Number of Participants per Category of History of Medical Disorders and Surgical Procedures | Baseline |
| Number of Participants per Type of Diabetes | Week 8, 12 |
| Number of Participants With Chronic Kidney Disease | Baseline |
Countries
France
Outcome results
None listed